Strides Up 12% on FDA Approval, Portfolio Gains

Comments Off Written on April 28th, 2014 by
Categories: Premium

This is a Capital Mind Premium post, sent on April 26, 2014.

Strides Arcolab has seen a surge in its stock price on news that the FDA continues its approvalfor Strides’ Bangalore oral dosage facility. It has gone up 12 to Rs. 526.

The rest of this content is only available to premium members.

Register for a premium membership today! Apart from this content you will get our proprietary research and weekly newsletter too!


Already a subscriber? Log in now!

Related Posts Plugin for WordPress, Blogger...


About the Author:
The man behind Capital Mind. Deepak is a co-founder at MarketVision, a financial knowledge company. Deepak also provides data research and consulting services, and now lives in Bangalore. Connect with him at